KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +68.2% (4yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +68.2% (4yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Olema Pharmaceuticals, Inc. NASDAQ:OLMA | $862.12M | $9.87 | Not rated | -5.1 | -64.15% |
Omeros Corporation NASDAQ:OMER | $632.20M | $8.74 | Not rated | 8.4 | +63.76% |
Rigel Pharmaceuticals, Inc. NASDAQ:RIGL | $607.79M | $32.85 | Undervalued | 1.7 | -7.14% |
4D Molecular Therapeutics, Inc. NASDAQ:FDMT | $461.60M | $8.83 | Not rated | -4.0 | +6.94% |
Prothena Corporation plc NASDAQ:PRTA | $431.91M | $8.25 | Not rated | -3.1 | -20.27% |
Verastem, Inc. NASDAQ:VSTM | $284.19M | $4.10 | Not rated | -2.1 | -20.06% |
Bicycle Therapeutics plc NASDAQ:BCYC | $281.05M | $4.05 | Not rated | -1.3 | -50.54% |
ADC Therapeutics S.A. NYSE:ADCT | $133.55M | $1.05 | Not rated | -1.2 | -66.25% |
Gossamer Bio, Inc. NASDAQ:GOSS | $38.00M | $0.16 | Not rated | -0.2 | +261.97% |
Continue the stock analysis
Jump to another research area for this company.